What did Carmell Therapeutics Corporation pay for Axolotl Biologix?

Carmell Therapeutics Corporation acquired Axolotl Biologix for $65.0M in 2023 (13.0x EBITDA), equivalent to 1.30x revenue. Target revenue was approximately $50.0M. Target EBITDA was approximately $5.0M.

What does Axolotl Biologix do?

Axolotl Biologix is a medical devices business.

What multiple did Carmell Therapeutics Corporation pay for Axolotl Biologix?

13.0x EBITDA and 1.30x revenue, based on disclosed deal value of $65.0M and disclosed financials.

M&A TRANSACTION · 2023

Axolotl Biologix acquired by Carmell Therapeutics Corporation

$65.0M· 13.0x EBITDA· 1.30x revenue

Target

Axolotl Biologix

Acquirer

Carmell Therapeutics Corporation

Strategic buyer

Disclosed financials at time of acquisition

Revenue

$50.0M

EBITDA

$5.0M

Deal Value

$65.0M

EV/EBITDA

13.0x

Context

This $65.0M acquisition of Axolotl Biologix by Carmell Therapeutics Corporation sits in the medical devices sub-vertical. The 13.0x EBITDA multiple paid in 2023 can be compared against the population median for medical devices transactions of similar size on our Medical Devices valuation hub. Carmell Therapeutics Corporation is acquiring as a strategic buyer; see how strategic acquirers typically price medical devices businesses on our Medical Devices strategic buyer-pool page.

Source

Data sourced from Press release. All figures reflect disclosed values at the time of the acquisition; no estimated or imputed data. Methodology

Value your own medical devices

Get an instant valuation range for your business. Backed by 25,592 real M&A transactions.

Compare your business to the Axolotl Biologix acquisition.

Citation: ExitValue.ai. (2023). Axolotl Biologix acquired by Carmell Therapeutics Corporation. https://exitvalue.ai/deals/axolotl-biologix-acquired-by-carmell-therapeutics-corporation-hc-2023-0043